“Chronic Rhinosinusitis with Nasal Polyps Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Rhinosinusitis with Nasal Polyps Market.
The Chronic Rhinosinusitis with Nasal Polyps Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Chronic Rhinosinusitis with Nasal Polyps Pipeline Report:
Companies across the globe are diligently working toward developing novel Chronic Rhinosinusitis with Nasal Polyps treatment therapies with a considerable amount of success over the years.
Chronic Rhinosinusitis with Nasal Polyps companies working in the treatment market are AstraZeneca, Amgen, Keymed Biosciences, GlaxoSmithKline, Genentech, Inc, Novartis, Upstream Bio Inc., Regeneron Pharma, Genrix (Shanghai) Biopharmaceutical, Guangdong Hengrui Pharmaceutical, Keymed Biosciences Co.Ltd, and others, are developing therapies for the Chronic Rhinosinusitis with Nasal Polyps treatment
Emerging Chronic Rhinosinusitis with Nasal Polyps therapies in the different phases of clinical trials are- NUCALA (mepolizumab), TEZSPIRE (tezepelumab), FASENRA (benralizumab), Tezepelumab, CM310, GSK3511294 (depemokimab), Omalizumab, Xolair, Verekitug (UPB-101), Dupilumab SAR231893, GR1802 injection, SHR-1905 Injection, CM310, and others are expected to have a significant impact on the Chronic Rhinosinusitis with Nasal Polyps market in the coming years.
In November 2024, The U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for DUPIXENT (dupilumab), developed by Sanofi and Regeneron Pharmaceuticals. This application requests approval for DUPIXENT as an additional maintenance treatment for adolescents aged 12 to 17 with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
In May 2024, The U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for DUPIXENT (dupilumab), developed by Sanofi and Regeneron Pharmaceuticals. This application requests approval for DUPIXENT as an additional maintenance treatment for adolescents aged 12 to 17 with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
Chronic Rhinosinusitis with Nasal Polyps Overview
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a long-lasting condition characterized by inflammation of the sinuses and nasal passages, often accompanied by the growth of benign, non-cancerous polyps (growths of tissue) inside the nasal cavity. It typically causes symptoms such as nasal congestion, loss of smell, facial pain or pressure, and nasal discharge. This condition can lead to significant discomfort and affect quality of life. The exact cause of CRSwNP is not fully understood, but it is often associated with factors such as allergies, asthma, and immune system dysfunction. Treatment may include medications such as nasal corticosteroids, oral steroids, and in some cases, surgery to remove the polyps.
Get a Free Sample PDF Report to know more about Chronic Rhinosinusitis with Nasal Polyps Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-pipeline-insight?
Emerging Chronic Rhinosinusitis with Nasal Polyps Drugs Under Different Phases of Clinical Development Include:
NUCALA (mepolizumab): GlaxoSmithKline
TEZSPIRE (tezepelumab): AstraZeneca/Amgen
FASENRA (benralizumab): AstraZeneca
Tezepelumab: AstraZeneca/Amgen
CM310: Keymed Biosciences
GSK3511294 (depemokimab): GlaxoSmithKline
Omalizumab: Genentech, Inc
Xolair: Novartis
Verekitug (UPB-101): Upstream Bio Inc.
Dupilumab SAR231893: Regeneron Pharmaceuticals
GR1802 injection: Genrix (Shanghai) Biopharmaceutical
SHR-1905 Injection: Guangdong Hengrui Pharmaceutical
CM310: Keymed Biosciences Co.Ltd
Chronic Rhinosinusitis with Nasal Polyps Route of Administration
Chronic Rhinosinusitis with Nasal Polyps pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Chronic Rhinosinusitis with Nasal Polyps Molecule Type
Chronic Rhinosinusitis with Nasal Polyps Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Chronic Rhinosinusitis with Nasal Polyps Pipeline Therapeutics Assessment
Chronic Rhinosinusitis with Nasal Polyps Assessment by Product Type
Chronic Rhinosinusitis with Nasal Polyps By Stage and Product Type
Chronic Rhinosinusitis with Nasal Polyps Assessment by Route of Administration
Chronic Rhinosinusitis with Nasal Polyps By Stage and Route of Administration
Chronic Rhinosinusitis with Nasal Polyps Assessment by Molecule Type
Chronic Rhinosinusitis with Nasal Polyps by Stage and Molecule Type
DelveInsight’s Chronic Rhinosinusitis with Nasal Polyps Report covers around 10+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Chronic Rhinosinusitis with Nasal Polyps product details are provided in the report. Download the Chronic Rhinosinusitis with Nasal Polyps pipeline report to learn more about the emerging Chronic Rhinosinusitis with Nasal Polyps therapies
Some of the key companies in the Chronic Rhinosinusitis with Nasal Polyps Therapeutics Market include:
Key companies developing therapies for Chronic Rhinosinusitis with Nasal Polyps are – Keymed Biosciences Co.Ltd, GlaxoSmithKline, Genrix (Shanghai) Biopharmaceutical Co., Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd, and others
Chronic Rhinosinusitis with Nasal Polyps Pipeline Analysis:
The Chronic Rhinosinusitis with Nasal Polyps pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Rhinosinusitis with Nasal Polyps with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Rhinosinusitis with Nasal Polyps Treatment.
Chronic Rhinosinusitis with Nasal Polyps key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Chronic Rhinosinusitis with Nasal Polyps Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Rhinosinusitis with Nasal Polyps market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Chronic Rhinosinusitis with Nasal Polyps drugs and therapies
Chronic Rhinosinusitis with Nasal Polyps Pipeline Market Drivers
Increasing Prevalence, Rising Awareness, Advances in Treatment Options, Growing Focus on Biologics, Unmet Medical Needs, Favorable Regulatory Support, Increased Investment in R&D, are some of the important factors that are fueling the Chronic Rhinosinusitis with Nasal Polyps Market.
Chronic Rhinosinusitis with Nasal Polyps Pipeline Market Barriers
However, High Treatment Costs, Long Development Timelines, Side Effects of Existing Therapies, Limited Treatment Efficacy, Regulatory Hurdles, Complexity of Disease Pathophysiology, and other factors are creating obstacles in the Chronic Rhinosinusitis with Nasal Polyps Market growth.
Scope of Chronic Rhinosinusitis with Nasal Polyps Pipeline Drug Insight
Coverage: Global
Key Chronic Rhinosinusitis with Nasal Polyps Companies: AstraZeneca, Amgen, Keymed Biosciences, GlaxoSmithKline, Genentech, Inc, Novartis, Upstream Bio Inc., Regeneron Pharma, Genrix (Shanghai) Biopharmaceutical, Guangdong Hengrui Pharmaceutical, Keymed Biosciences Co.Ltd, and others
Key Chronic Rhinosinusitis with Nasal Polyps Therapies: NUCALA (mepolizumab), TEZSPIRE (tezepelumab), FASENRA (benralizumab), Tezepelumab, CM310, GSK3511294 (depemokimab), Omalizumab, Xolair, Verekitug (UPB-101), Dupilumab SAR231893, GR1802 injection, SHR-1905 Injection, CM310, and others
Chronic Rhinosinusitis with Nasal Polyps Therapeutic Assessment: Chronic Rhinosinusitis with Nasal Polyps current marketed and Chronic Rhinosinusitis with Nasal Polyps emerging therapies
Chronic Rhinosinusitis with Nasal Polyps Market Dynamics: Chronic Rhinosinusitis with Nasal Polyps market drivers and Chronic Rhinosinusitis with Nasal Polyps market barriers
Request for Sample PDF Report for Chronic Rhinosinusitis with Nasal Polyps Pipeline Assessment and clinical trials
Table of Contents
1. Chronic Rhinosinusitis with Nasal Polyps Report Introduction
2. Chronic Rhinosinusitis with Nasal Polyps Executive Summary
3. Chronic Rhinosinusitis with Nasal Polyps Overview
4. Chronic Rhinosinusitis with Nasal Polyps- Analytical Perspective In-depth Commercial Assessment
5. Chronic Rhinosinusitis with Nasal Polyps Pipeline Therapeutics
6. Chronic Rhinosinusitis with Nasal Polyps Late Stage Products (Phase II/III)
7. Chronic Rhinosinusitis with Nasal Polyps Mid Stage Products (Phase II)
8. Chronic Rhinosinusitis with Nasal Polyps Early Stage Products (Phase I)
9. Chronic Rhinosinusitis with Nasal Polyps Preclinical Stage Products
10. Chronic Rhinosinusitis with Nasal Polyps Therapeutics Assessment
11. Chronic Rhinosinusitis with Nasal Polyps Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Chronic Rhinosinusitis with Nasal Polyps Key Companies
14. Chronic Rhinosinusitis with Nasal Polyps Key Products
15. Chronic Rhinosinusitis with Nasal Polyps Unmet Needs
16 . Chronic Rhinosinusitis with Nasal Polyps Market Drivers and Barriers
17. Chronic Rhinosinusitis with Nasal Polyps Future Perspectives and Conclusion
18. Chronic Rhinosinusitis with Nasal Polyps Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
